Previous 10 | Next 10 |
2023-03-31 06:00:00 ET Summary Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it’s time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter cr...
2023-03-23 08:56:52 ET Popular biotech exchange traded fund SPDR S&P Biotech ETF ( NYSEARCA: XBI ) dropped more than 3% on Wednesday. As a result, the ETF reached a new 8-month low. XBI touched $73.06 a share on Wednesday which marked its lowest level dating back to ...
2023-03-16 11:59:04 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Conference Call March 16, 2023 08:30 A.M. ET Company Participants Alicia Grande - VP, CFO, and Treasurer Patrick J. McEnany - Chairman, President, and CEO Jeff Del Carmen - Chief Commer...
2023-03-15 16:19:15 ET Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q4 Non-GAAP EPS of $0.31 beats by $0.11 . Revenue of $60.76M (+58.6% Y/Y) beats by $0.12M . Cash and Equivalents were $298 million as of December 31, 2022. Achieved Record 2022 ...
Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecas...
2023-03-13 06:30:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the most important things about finding stocks to buy is having a diversified portfolio. You want to spread your money out in different sectors so you’re not hurt if one part of t...
CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...
CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients li...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the latest on inflation and interest rates suggesting more challenges ahead for the economy and the markets, there’s renewed appeal for defensive plays. However, those are not the only stocks for cautious investors ...
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to the Community CORAL GABLES, Fla., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmac...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...